© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Dallas-Moxifloxacin ophthalmic solution (Vigamox 0.5%, Alcon Laboratories) was approved by the FDA on April 16 for the treatment of bacterial conjunctivitis, following a 6-month review of the drug.